Special Episode: Breaking Down the FDA’s Latest Migraine Therapy Approvals with Dr. Stewart Tepper

Stewart Tepper, MD

A special episode of the NeurologyLive^® Mind Moments^® podcast is now live! Scroll down to listen or click here to subscribe on your favorite streaming service.

The Mind Moments^® podcast features exclusive interviews with leaders in the field discussing the latest research and disease management strategies across the breadth of neurology, including epilepsy, multiple sclerosis (MS), Parkinson disease, dementia, sleep disorders, and more.

In this special episode, "Breaking Down the FDA's Latest Migraine Therapy Approvals" Stewart Tepper, MD, professor of neurology at the Geisel School of Medicine at Dartmouth, discusses the agency's latest decisions to approve STS101 (Atzumi; Satsuma Pharmaceuticals) and CT-132 (Click Therapeutics) for the acute and preventive treatment of migraine. In this 2-part episode, Tepper breaks down the pharmacological profile and clinical utility of DHE, the formulation behind STS101, and how the latest delivery innovations may expand its use in acute migraine care. He also dives into the approval data behind CT-132, the first-ever FDA-approved prescription digital therapeutic for migraine, and what it could mean for patients and clinicians alike. Above all, Tepper highlights the need for clinician education as novel therapeutics reshape the treatment landscape and offers insight into how these new tools could improve patient outcomes with fewer side effects and better accessibility.

For more of NeurologyLive's coverage of STS101 and CT-132 for migraine, head here: FDA Approves STS101 Nasal Powder as New Treatment for Acute Migraine

FDA Approves CT-132 as First Digital Therapeutic for Preventive Treatment of Episodic Migraine

EPISODE BREAKDOWN

• 1:10 – Overview of DHE, patient suitability, and STS101’s place in treatment
• 6:05 – Efficacy and safety data from the ASCEND and SUMMIT trials for STS101
• 10:20 – The expanding migraine toolbox and need for clinician education
• 15:10 – CT-132’s first-in-class status and clinical trial data
• 16:25 – Clinical use of CT-132 as an add-on preventive
• 19:30 – The knowledge gap on digital therapeutics and educating the neurology community
• 23:00 – Future directions and hopes for expanded CT-132 research

Click here to subscribe to the Mind Moments^® podcast. Be sure to leave a rating and review for the show. Thanks for listening!

REFERENCES
1. Satsuma Pharmaceuticals Announces U.S. FDA Approval for Atzumi™ (Dihydroergotamine) Nasal Powder for the Acute Treatment of Migraine. News Release. Published April 30, 2025. Accessed July 18, 2025. https://investors.satsumarx.com/2025-04-30-Satsuma-Pharmaceuticals-Announces-U-S-FDA-Approval-for-Atzumi-TM-Dihydroergotamine-Nasal-Powder-for-the-Acute-Treatment-of-Migraine
2. Click Therapeutics Announces FDA Marketing Authorization for CT-132, the First Prescription Digital Therapeutic for the Preventive Treatment of Episodic Migraine in the United States. News release. Click Therapeutics. April 15, 2025. Accessed July 15, 2025. https://www.biospace.com/press-releases/click-therapeutics-announces-fda-marketing-authorization-for-ct-132-the-first-prescription-digital-therapeutic-for-the-preventive-treatment-of-episodic-migraine-in-the-united-states